No CrossRef data available.
Article contents
Uptake and initial use of novel antimicrobial agents at community hospitals in western Pennsylvania
Published online by Cambridge University Press: 22 August 2019
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Research Brief
- Information
- Copyright
- © 2019 by The Society for Healthcare Epidemiology of America. All rights reserved.
Footnotes
PREVIOUS PRESENTATION. This study was presented as an abstract at ID Week 2018 on October 6, 2018 in San Francisco, California.
References
Schulz, LT, Kim, SY, Hartsell, A, Rose, WE. Antimicrobial stewardship during a time of rapid antimicrobial development: potential impact on industry for future investment. Diagn Microbiol Infect Dis 2019. pii: S0732-8893(19)30344-X. Advance online publication.Google Scholar
Shields, RK, Potoski, BA, Haidar, G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016;63:1615–1618.CrossRefGoogle ScholarPubMed
Gelfand, MS, Cleveland, KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2015;61:853–855.CrossRefGoogle ScholarPubMed
Delaportas, DJ, Estrada, SJ, Darmelio, M. Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin. Pharmacotherapy 2017;37:e90–e92.CrossRefGoogle ScholarPubMed
Shields, RK, Nguyen, MH, Chen, L, Press, EG, Kreiswirth, BN, Clancy, CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infection. Antimicrob Agent Chemother 2018;62:e02497–17.CrossRefGoogle Scholar
Plant, AJ, Dunn, A, Porter, RJ. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Psuedomonas aeruginosa pneumonia. Expert Rev Anti Infect Ther 2018;16:367–368.CrossRefGoogle Scholar
Cox, E, Nambiar, S, Badan, L. Needed: antimicrobial development. New Eng J Med 2019;380:783–785.CrossRefGoogle ScholarPubMed
Antibacterial therapies for patients with an unmet need for the treatment of serious bacterial diseases guidance for industry. US Food and Drug Administration website. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM359184.pdf Published August 2017. Accessed February 18, 2019.Google Scholar